Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1590/1980-57642020dn14-010004 http://hdl.handle.net/11449/200137 |
Resumo: | Dementia is a chronic neurodegenerative disease and Alzheimer’s disease (AD) is the most prevalent type. Objective: To describe the drug monitoring of patients enrolled in a Clinical Protocol and Therapeutic Guidelines of Alzheimer’s Disease (PCDTDA) in Brazil. Methods: A descriptive study based on interviews conducted in 2017 was performed. Patients diagnosed with Alzheimer’s disease (AD) enrolled on the PCDTDA were included. The variables assessed were age, sex, time since diagnosis, clinical parameters of Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR), drug therapy used and AD drug collection. Results: The drug monitoring of 143 patients was evaluated. Observing the requirements of the screening tests for patient enrolment on the PCDTDA, all patients had scores for at least one MMSE and CDR assessment at protocol admission. None of the patients underwent the first reassessment of the effectiveness of AD drug therapy or the semiannual reassessment. Conclusion: Although PCDTDA provides the best evidence of AD treatment, the data showed failures in the monitoring of the effectiveness of AD drug therapy at dispensing. |
id |
UNSP_db2aca67b7fc1ad231a20cdb048714af |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/200137 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s diseaseMonitoramento do cumprimento do protocolo clínico e diretrizes terapêuticas da doença de alzheimer.Clinical protocolsDementiaDrug monitoringDrug safetyPatient safetyDementia is a chronic neurodegenerative disease and Alzheimer’s disease (AD) is the most prevalent type. Objective: To describe the drug monitoring of patients enrolled in a Clinical Protocol and Therapeutic Guidelines of Alzheimer’s Disease (PCDTDA) in Brazil. Methods: A descriptive study based on interviews conducted in 2017 was performed. Patients diagnosed with Alzheimer’s disease (AD) enrolled on the PCDTDA were included. The variables assessed were age, sex, time since diagnosis, clinical parameters of Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR), drug therapy used and AD drug collection. Results: The drug monitoring of 143 patients was evaluated. Observing the requirements of the screening tests for patient enrolment on the PCDTDA, all patients had scores for at least one MMSE and CDR assessment at protocol admission. None of the patients underwent the first reassessment of the effectiveness of AD drug therapy or the semiannual reassessment. Conclusion: Although PCDTDA provides the best evidence of AD treatment, the data showed failures in the monitoring of the effectiveness of AD drug therapy at dispensing.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)School of Pharmaceutical Sciences Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)São Paulo State University (UNESP) Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)School of Pharmaceutical Sciences Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)São Paulo State University (UNESP) Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)CAPES: 001CNPq: 131206/2017-6FAPESP: 2018/07501-9CNPq: 459461/2014-1Universidade Estadual Paulista (Unesp)Forgerini, Marcela [UNESP]Mastroianni, Patrícia de Carvalho [UNESP]2020-12-12T01:58:41Z2020-12-12T01:58:41Z2020-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article24-27application/pdfhttp://dx.doi.org/10.1590/1980-57642020dn14-010004Dementia e Neuropsychologia, v. 14, n. 1, p. 24-27, 2020.1980-5764http://hdl.handle.net/11449/20013710.1590/1980-57642020dn14-010004S1980-576420200001000242-s2.0-85081228267S1980-57642020000100024.pdfScopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengDementia e Neuropsychologiainfo:eu-repo/semantics/openAccess2023-10-12T06:03:44Zoai:repositorio.unesp.br:11449/200137Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462023-10-12T06:03:44Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease Monitoramento do cumprimento do protocolo clínico e diretrizes terapêuticas da doença de alzheimer. |
title |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease |
spellingShingle |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease Forgerini, Marcela [UNESP] Clinical protocols Dementia Drug monitoring Drug safety Patient safety |
title_short |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease |
title_full |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease |
title_fullStr |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease |
title_full_unstemmed |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease |
title_sort |
Monitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s disease |
author |
Forgerini, Marcela [UNESP] |
author_facet |
Forgerini, Marcela [UNESP] Mastroianni, Patrícia de Carvalho [UNESP] |
author_role |
author |
author2 |
Mastroianni, Patrícia de Carvalho [UNESP] |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Forgerini, Marcela [UNESP] Mastroianni, Patrícia de Carvalho [UNESP] |
dc.subject.por.fl_str_mv |
Clinical protocols Dementia Drug monitoring Drug safety Patient safety |
topic |
Clinical protocols Dementia Drug monitoring Drug safety Patient safety |
description |
Dementia is a chronic neurodegenerative disease and Alzheimer’s disease (AD) is the most prevalent type. Objective: To describe the drug monitoring of patients enrolled in a Clinical Protocol and Therapeutic Guidelines of Alzheimer’s Disease (PCDTDA) in Brazil. Methods: A descriptive study based on interviews conducted in 2017 was performed. Patients diagnosed with Alzheimer’s disease (AD) enrolled on the PCDTDA were included. The variables assessed were age, sex, time since diagnosis, clinical parameters of Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR), drug therapy used and AD drug collection. Results: The drug monitoring of 143 patients was evaluated. Observing the requirements of the screening tests for patient enrolment on the PCDTDA, all patients had scores for at least one MMSE and CDR assessment at protocol admission. None of the patients underwent the first reassessment of the effectiveness of AD drug therapy or the semiannual reassessment. Conclusion: Although PCDTDA provides the best evidence of AD treatment, the data showed failures in the monitoring of the effectiveness of AD drug therapy at dispensing. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-12T01:58:41Z 2020-12-12T01:58:41Z 2020-01-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/1980-57642020dn14-010004 Dementia e Neuropsychologia, v. 14, n. 1, p. 24-27, 2020. 1980-5764 http://hdl.handle.net/11449/200137 10.1590/1980-57642020dn14-010004 S1980-57642020000100024 2-s2.0-85081228267 S1980-57642020000100024.pdf |
url |
http://dx.doi.org/10.1590/1980-57642020dn14-010004 http://hdl.handle.net/11449/200137 |
identifier_str_mv |
Dementia e Neuropsychologia, v. 14, n. 1, p. 24-27, 2020. 1980-5764 10.1590/1980-57642020dn14-010004 S1980-57642020000100024 2-s2.0-85081228267 S1980-57642020000100024.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Dementia e Neuropsychologia |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
24-27 application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1799964529835114496 |